BTIG Reiterates Buy on Abivax, Maintains $150 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.4%

Neg 0% Neu 88.4% Pos 0%

BTIG analyst Julian Harrison reiterates Abivax (NASDAQ:ABVX) with a Buy and maintains $150 price target.

Comments

No comments yet. Be the first!